

Screening Run-In
100 mg
Placebo
Eosinophil Recovery
8 wks
Screening Period
56 wks
Double-Blind Treatment Period
32 wks
Washout/ Safety Follow-Up

Figure 1



Placebo N / Rate
Benralizumab N / Rate
TV
Rate Reduction [95% CI]
Overall (N=101) 50 / 0.91 51 / 0.93 −2% [−51%, 31%]
Peripheral Blood Eos
>= 200 (N=46) 24 / 0.97 22 / 0.63 35% [−24%, 65%]
< 200 (N=53) 25 / 0.78 28 / 1.19 −53% [−162%, 11%]
>= 300 (N=25) 8 / 0.93 17 / 0.33 65% [−2%, 88%]
< 300 (N=74) 41 / 0.86 33 / 1.27 −47% [−127%, 4%]
200 − 300 (N=21) 16 / 0.99 5 / 1.67 −69% [−280%, 24%]
−90 −60 −30 0 30 60 90
Rate Reduction (%)

Figure 2



MEAN FEV1 PREDICTED CHANGE FROM BASELINE (%)
12
10
8
6
4
2
0
-2
-4
-6
-8
-10
D29 D57 D113 D169 D225 D281 D337 D393 D477 D561
PLACEBO (n) 44 44 44 44 44 43 42 44 29 8
Benralizumab (n) 40 40 40 40 40 39 38 37 22 9
VISIT (1)
TREATMENT GROUP: PLACEBO (N-44) Benralizumab 100MG (N-40)

Figure 3



Placebo N/Estimate
Benralizumab N/Estimate
Difference [95%CI]
Overall
46/-0.046
42/0.091
0.137[0.010,0.264]
Overall w/o outlier
46/-0.046
41/0.055
0.101[0.004,0.198]
EOS>=200
21/-0.045
19/0.203
0.249[0.009,0.489]
EOS>=200 w/o outlier
21/-0.045
18/0.122
0.167[0.011,0.324]
EOS<200
24/-0.029
23/-0.000
0.029[-0.099,0.157]
EOS>=300
8/-0.204
14/0.204
0.283[-0.158,0.723]
EOS>=300 w/o outlier
13/0.097
13/0.097
0.173[-0.084,0.429]
EOS<300
37/-0.029
28/0.034
0.063[-0.041,0.166]
EOS 200-300
13/-0.017
5/0.148
0.165[-0.042,0.371]
-0.2
0.0
0.2
0.4
0.6
0.8
Treatment Difference (L)

Figure 4



Placebo
N / ESTIMATE
Benralizumab
N / ESTIMATE
Difference [95% CI]
Overall (N=86) 44 / -0.079 42 / 0.047 0.125 [-0.004, 0.254]
Peripheral Blood Eos
>= 200 (N=38) 19 / -0.083 19 / 0.149 0.231 [-0.018, 0.481]
< 200 (N=47) 24 / -0.058 23 / -0.035 0.023 [-0.093, 0.138]
>= 300 (N=20) 6 / -0.127 14 / 0.157 0.284 [-0.169, 0.739]
< 300 (N=65) 37 / -0.055 28 / -0.010 0.045 [-0.061, 0.150]
200 - 300 (N=18) 13 / -0.035 5 / 0.060 0.098 [-0.154, 0.351]
-0.2
0.0
0.2
0.4
0.6
0.8
Difference

Figure 5



Placebo
N / ESTIMATE
Benralizumab
N / ESTIMATE
Difference [95% CI]
Overall (N=88) 46 / -3.957 42 / -3.928 0.030 [-5.315, 5.374]
Peripheral Blood Eos
>= 200 (N=40) 21 / -4.833 19 / -8.233 -3.400 [-12.472, 5.672]
< 200 (N=47) 24 / -3.334 23 / -0.395 2.940 [-3.844, 9.724]
>= 300 (N=22) 8 / -5.959 14 / -11.158 -5.199 [-20.755, 10.357]
< 300 (N=65) 37 / -3.510 28 / -0.444 3.066 [-2.614, 8.745]
200 - 300 (N=18) 13 / -4.543 5 / 1.340 5.883 [-6.395, 18.161]
-35 -25 -15 -5 0 5 10 15 20
Difference

Figure 6



Placebo
N / ESTIMATE
Benralizumab
N / ESTIMATE
Difference [95% CI]
Overall (N=88) 46 / -3.178 42 / -6.264 -3.086 [-9.325, 3.153]
Peripheral Blood Eos
>= 200 (N=40) 21 / -2.725 19 / -13.514 -10.789 [-21.551, -0.027]
< 200 (N=47) 24 / -4.442 23 / -0.102 4.340 [-3.043, 11.724]
>= 300 (N=22) 8 / -2.883 14 / -17.135 -14.251 [-31.734, 3.231]
< 300 (N=65) 37 / -3.546 28 / -0.774 2.771 [-3.532, 9.075]
200 – 300 (N=18) 13 / -2.741 5 / -1.499 1.243 [-12.695, 15.180]
-35 -25 -15 -5 0 5 10 15 20
Difference

Figure 7




EOSINOPHILS (ABS) (X10E3/UL)
0.40
0.35
0.30
0.25
0.20
0.15
0.10
0.05
0.00
BSL D29 D57 D113 D169 D225 D281 D337 D393 D477 D561
PLACEBO (n) 49 45 45 43 45 43 43 42 43 36 19
Benralizumab (n) 50 48 47 47 47 43 42 41 39 28 17
VISIT (1)
TREATMENT GROUP: PLACEBO (N-50) Benralizumab 100MG (N-51)
[1] DATA BEYOND DAY 337 (MARKED BY THE VERTICAL REFERENCE LINE) OCCUR AFTER THE LAST SCHEDULED DOSE OF STUDY DRUG. BSL-BASELINE, DX-DAY X.

Figure 8



[1] DATA BEYOND DAY 337 (MARKED BY THE VERTICAL REFERENCE LINE) OCCUR AFTER THE LAST SCHEDULED DOSE OF STUDY DRUG. BSL-BASELINE, DX-DAY X.

Figure 9





EOSINOPHILS (ABS) (X10E3/UL)
0.40
0.35
0.30
0.25
0.20
0.15
0.10
0.05
0.00
BSL D29 D57 D113 D169 D225 D281 D337 D393 D477 D561
PLACEBO (n) 49 45 45 43 45 43 43 42 43 36 19
Benralizumab (n) 50 48 47 47 47 43 42 41 39 28 17
VISIT (1)
TREATMENT GROUP: PLACEBO (N-50) Benralizumab 100MG (N-51)

Figure 10



Visit 1 occurs in week -4.
Visit 2 occurs in week -3.
Visit 3 occurs in week -1.
Visit 4 occurs in week 0.
Visits 4-7 occur in weeks 0-8.
Visits 8-18 occur in weeks 12-52.
Visit 19 occurs in week 56.
Visit 20 occurs in week 60.

Figure 11



Visit 1 occurs in week -4.
Visit 2 occurs in week -3.
Visit 3 occurs in week -1.
Visit 4 occurs in week 0.
Visits 4-7 occur in weeks 0-8.
Visits 8-18 occur in weeks 12-52.
Visit 19 occurs in week 56.
Visit 20 occurs in week 60.

Figure 12